These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1764953)

  • 1. Atenolol and ischaemic heart disease: an overview.
    Cruickshank JM; McAinsh J
    Curr Med Res Opin; 1991; 12(8):485-96. PubMed ID: 1764953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.
    Mulcahy D; Keegan J; Cunningham D; Quyyumi A; Crean P; Park A; Wright C; Fox K
    Lancet; 1988 Oct; 2(8614):755-9. PubMed ID: 2901609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of beta-blockade on heart rate variability in patients with coronary artery disease.
    Niemelä MJ; Airaksinen KE; Huikuri HV
    J Am Coll Cardiol; 1994 May; 23(6):1370-7. PubMed ID: 8176095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia.
    Deedwania PC; Carbajal EV; Nelson JR; Hait H
    J Am Coll Cardiol; 1991 Mar; 17(4):963-9. PubMed ID: 1999634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diurnal variation of ischemic response to exercise in patients receiving a once-daily dose of beta-blockers. Implications for exercise testing and prescription of exercise and training heart rates.
    Franklin BA; Gordon S; Timmis GC
    Chest; 1996 Jan; 109(1):253-7. PubMed ID: 8549193
    [No Abstract]   [Full Text] [Related]  

  • 6. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.
    Van de Werf F; Janssens L; Brzostek T; Mortelmans L; Wackers FJ; Willems GM; Heidbüchel H; Lesaffre E; Scheys I; Collen D
    J Am Coll Cardiol; 1993 Aug; 22(2):407-16. PubMed ID: 8335810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia.
    Guth BD; Heusch G; Seitelberger R; Matsuzaki M; Ross J
    Eur Heart J; 1987 Dec; 8 Suppl L():61-8. PubMed ID: 3451884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group.
    Dargie HJ; Ford I; Fox KM
    Eur Heart J; 1996 Jan; 17(1):104-12. PubMed ID: 8682116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study.
    Reyes E; Stirrup J; Roughton M; D'Souza S; Underwood SR; Anagnostopoulos C
    J Nucl Med; 2010 Jul; 51(7):1036-43. PubMed ID: 20554740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment with beta-blockers in patients with acute coronary syndrome].
    Nozawa T; Inoue H
    Nihon Rinsho; 1998 Oct; 56(10):2612-6. PubMed ID: 9796327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol.
    Ramsdale DR; Faragher EB; Bennett DH; Bray CL; Ward C; Cruickshank JM; Yusuf S; Sleight P
    Am Heart J; 1982 Apr; 103(4 Pt 1):459-67. PubMed ID: 6121479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].
    Mafrici A; Mauri F; Maggioni AP; Franzosi MG; Santoro L; De Vita C
    G Ital Cardiol; 1995 Mar; 25(3):353-64. PubMed ID: 7642042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian variation of the total ischemic burden and influence by beta-blocking agents.
    Fox KM; Mulcahy DA
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S100-4. PubMed ID: 11527111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will bedtime dose of atenolol be more effective in secondary prevention of coronary artery disease?
    Dileep-Kumar P; Sahasranam KV; Nair RG
    J Indian Med Assoc; 1992 Dec; 90(12):313. PubMed ID: 1304016
    [No Abstract]   [Full Text] [Related]  

  • 15. [Long term effects of the beta-adrenergic blocking agent atenolol (Tenormin) on coronary heart disease: a study of 125 patients (author's transl)].
    Langbehn AF; Burmeister G; Horst H; Sonntag F; Klempien EJ
    Med Klin; 1978 Jan; 73(3):101-5. PubMed ID: 622059
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal control of myocardial ischaemia: the benefit of a fixed combination of atenolol and nifedipine in patients with chronic stable angina.
    el-Tamimi H; Davies GJ
    Br Heart J; 1992 Sep; 68(3):291-5. PubMed ID: 1389761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic management of ischemic heart disease with beta-blockers and calcium channel blockers.
    Pearle DL
    Am Heart J; 1990 Sep; 120(3):739-42; discussion 743-5. PubMed ID: 1975155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in ischaemic myocardial potassium leakage after treatment with the calcium antagonist anipamil or the beta-blocker atenolol.
    Kirchengast M
    Arzneimittelforschung; 1990 Aug; 40(8):868-71. PubMed ID: 2242078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.
    Lancet; 1986 Jul; 2(8498):57-66. PubMed ID: 2873379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-ischaemic and anti-anginal activity of atenolol, nifedipine and their combination in stable, chronic effort angina.
    Lai C; Onnis E; Pirisi R; Orani E; Delogu G; Cherchi A
    Drugs Exp Clin Res; 1988; 14(11):699-705. PubMed ID: 3073077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.